| 28.65 2.26 (8.56%) | 10-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 36.3 |
1-year : | 42.4 |
| Resists | First : | 31.07 |
Second : | 36.3 |
| Pivot price | 28.33  |
|||
| Supports | First : | 26.46 |
Second : | 23.61 |
| MAs | MA(5) : | 27.03 |
MA(20) : | 28.08 |
| MA(100) : | 21.73 |
MA(250) : | 24.6 |
|
| MACD | MACD : | 0.8 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 29.3 |
D(3) : | 22.2 |
| RSI | RSI(14): 60.2 |
|||
| 52-week | High : | 42.56 | Low : | 13.22 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GPCR ] has closed below upper band by 44.3%. Bollinger Bands are 24.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.88 - 29.07 | 29.07 - 29.24 |
| Low: | 26.17 - 26.41 | 26.41 - 26.62 |
| Close: | 28.27 - 28.66 | 28.66 - 29.01 |
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Tue, 14 Oct 2025
Structure Therapeutics Inc. (GPCR): Investor Outlook With A 142% Potential Upside - DirectorsTalk Interviews
Sat, 11 Oct 2025
Structure Therapeutics (GPCR): Examining Valuation After Recent Share Price Momentum - Yahoo Finance
Tue, 07 Oct 2025
Structure Therapeutics Inc. (GPCR): Analyst Ratings Point to a 155% Upside, Propelling Investor Interest - DirectorsTalk Interviews
Fri, 03 Oct 2025
Structure Therapeutics: The Dark Horse In The Oral Obesity GLP-1 Arena (NASDAQ:GPCR) - Seeking Alpha
Sat, 27 Sep 2025
Why Structure Therapeutics (GPCR) Is Up 6.0% After Showcasing Obesity Pipeline and R&D Advances - simplywall.st
Tue, 23 Sep 2025
Structure Therapeutics Inc. (GPCR) Stock Analysis: A Biotech Powerhouse with a Potential 199% Upside - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 58 (M) |
| Shares Float | 134 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 96.6 (%) |
| Shares Short | 4,850 (K) |
| Shares Short P.Month | 6,800 (K) |
| EPS | -3.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -15.6 % |
| Return on Equity (ttm) | -21.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -163 (M) |
| Levered Free Cash Flow | -99 (M) |
| PE Ratio | -9.1 |
| PEG Ratio | 0 |
| Price to Book value | 2.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|